Shutterstock
China is rapidly gaining on the United States when it comes to creating technology that mitigates disease threats and developing pharmaceuticals faster, and its a phenomenon driven by a philosophy that the state, military, and the private sector are one in the same.
That was the testimony of Tara J. OToole, senior fellow and executive vice president at In-Q-Tel, before the U.S. Senate Armed Services Subcommittee on Emerging Threats and Capabilities. The hearing, Biological Threats to U.S. National Security, examined everything from Chinas push to develop biotechnology infrastructure to luring research scientists away from the United States to work in China.
China has said repeatedly and forcefully, and theyre backing up their words with actions, that they intend to own the biorevolution, OToole said. And they are building the infrastructure, the talent pipeline, the regulatory system, and the financial system they need to do that.
China is partly accomplishing this by combining its internet giants, such as Alibaba, with its biotech companies. The combined strength of these companies research focuses on the industrialization of artificial intelligence in which China is institutionalizing it whereas the United States is only experimenting with it, OToole added.
Chinas goal is to make biotechnology 5 percent of the countrys GDP by 2020. China has changed regulations for its own version of the Food and Drug Administration to be more like that of the United States in order to more easily market to the world. The country has created a talent pipeline that incentivizes its own students to go into the life sciences and bioengineering. China also has at least 20 programs intended to bring scientific talent from the rest of the world.
There are good reasons China is going after the biorevolution: it has the highest incidences of cancer on earth and the population is aging. It also must find an affordable way to deliver health care to a rising middle class.
And China is delivering health care to the world. The country is the largest producer of active pharmaceutical ingredients. However, reliance on foreign pharmaceuticals has national security implications. As many as 80 to 100 percent of critical drugs are manufactured outside the United States. U.S Sen. Gary Peters (D-MI) told the committee that following the 2001 anthrax attacks, the U.S. was dependent on a single foreign source for a broad-spectrum antibiotic to treat anthrax.
To what extent is the U.S. reliant on foreign sources for key drug products and medical supplies such as syringes and needles and other critical medical supplies that we would need to respond to a biological attack today? Peters asked the panel of experts.
The United States is critically dependent on China for several drugs and has been shipping manufacturing capacity to Asia for more than a decade.
There isnt a CEO of a major pharma company that hasnt been recruited by China to build facilities there, OToole said.
To address the drug supply chain, the United States has begun exploring the possibility of using synthetic biology to make active pharmaceutical ingredients, especially in response to epidemics.
If there were a natural pandemic in which the entire world needed drugs, Im sure China, as we would, take care of its own people first. Yet, we dont have the surge capacity to produce enough very common, well-used medicine in time to deal with an epidemic, OToole said.
Thomas Inglesby, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, told the committee that the U.S. treats medicines too much like commodities that can be sourced for the lowest price somewhere in the world.
In a crisis, everyone in every part of the world would be looking for medicine at the same time, Inglesby said. There should be at least a strategic examination of the kinds of things we must have, and we should consider how to bring some of those medicines back to the U.S. Obviously that cant be done with all medicines. Were an interconnected world. But for national health crises, we should be thinking about making them here.
Part of the problem is that the United States has not done a good job at translating biology to products, OToole said, or building infrastructure for securing and promoting the bioeconomy. Our translational infrastructure for biology is mostly coming from small start-up companies in the private sector, which are the innovation engines for biology, but do not provide the robust infrastructure to manage epidemics, whether deliberate or natural.
The experts made the following recommendations:
* Take on synthetic biology as a national security priority;* Use the National Defense Education Act to improve access to stem education and establish greater scientific careers within the U.S. government;* The contingency fund levels for the Centers for Disease Control and Prevention and USAID should be increased and sustained;* Support and strengthen the militarys infectious disease research laboratories;* Provide strong, coherent leadership at the National Security Council essential for guaranteeing effective oversight, long before a crisis emerges;* The U.S. Department of Agriculture should prioritize stronger crop surveillance, animal wildlife surveillance, more support for animal vaccine development, and more funding for agricultural biodefense overall;* Strongly support the biological weapons convention.
During epidemics, the U.S. should be able to immediately create diagnostics that could be used similarly to a pregnancy test so that people can determine for themselves who is sick and who isnt. Officials should be able to rapidly develop a new vaccine in response to an epidemic, OToole added.
These same tools also apply to diseases that affect agriculture and the U.S. animal supply. More than half of all infections that people contract are spread by animals.
Ill start by acknowledging that mother nature is a really good terrorist, Julie L. Gerberding, co-chair of the Commission on Strengthening Americas Health Security at the Center for Strategic and International Studies, told the committee. China today is experiencing a dreadful outbreak of swine fever that has probably cost the death or culling of at least 50 percent of their entire population of pork which is a major source of protein for people in China. So, this is a major socioeconomic threat to the state of China today and thats mother nature.
Swine fever, however, is not spread to humans, though it has a devastating economic impact. And U.S. farmers are concerned about trade and travel bringing such infectious diseases to this country.
I would say that the first alarming statistic is that we spend probably about 100 times less on agricultural threats than we do on human threats, Inglesby said. I think there are many reasons for this. But one includes a kind of reluctance within the U.S. government to talk about this threat until quite recently.
Continue reading here:
Chinese biotechnology dominates US Senate hearing on biological threats - Homeland Preparedness News
- Biotechnology Research Among Science Returned to Earth - ISS National Lab - May 5th, 2024
- Program to prepare next generation of biotech experts receives renewed funding - The University of Rhode Island - May 5th, 2024
- Designing drugs with reversible activity - Nature.com - May 5th, 2024
- ScienceLIVE helps answer 'What the Heck is Biotech?' for career-minded adults - UMass Medical School - May 5th, 2024
- Boston Micro Fabrication Launches BMF Biotechnology Inc. to Advance Use of 3D BioChips in Pharmaceutical and ... - Morningstar - May 5th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 - Business Wire - May 5th, 2024
- WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions - FiercePharma - May 5th, 2024
- Boston Micro Fabrication Launches BMF Biotechnology Inc. to Advance Use of 3D BioChips in Pharmaceutical and ... - Business Wire - May 5th, 2024
- U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033 - BioSpace - April 16th, 2024
- 6 biotechnology universities in the USA developing young talent - Labiotech.eu - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - NBC Right Now - April 16th, 2024
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewswire - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - pdclarion.com - April 16th, 2024
- BIO's top lobbyist heads out the door - FiercePharma - April 16th, 2024
- BIO's top lobbyist exits, signaling reorganization - STAT - STAT - April 16th, 2024
- Biotech Rebound Could Boost This ETF - ETF Trends - April 16th, 2024
- US National Security, China and Biotechnology in 2024 - BioSpace - April 8th, 2024
- How to Invest in Biotechnology (Updated 2024) - Nasdaq - April 8th, 2024
- Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression - Nature.com - April 8th, 2024
- Genetically encoding colors and images into bioengineered microbial materials - Nature.com - April 8th, 2024
- Ambition and urgency: Biotechnology and Biomanufacturing in the EU - EURACTIV - April 8th, 2024
- Scientists create plastic-free vegan leather that dyes itself, grown from bacteria - Phys.org - April 8th, 2024
- For national security, the U.S. must maintain its biotech dominance - STAT - April 8th, 2024
- LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside? - Yahoo Finance - April 8th, 2024
- Is biotechnology a good career? Here are the pros and cons - Labiotech.eu - March 18th, 2024
- Saving Biology With Blue Biotechnology - The Maritime Executive - March 18th, 2024
- 30 Biggest Biotechnology Companies in the World - Yahoo Finance - March 18th, 2024
- WuXi out of biotech trade group, U.S. and China relations to blame - STAT - March 18th, 2024
- Can Biotechnology Save the Fashion Industry? - EARTH.ORG - March 18th, 2024
- Huber high-precision temperature control solutions for the pharmaceutical industry and biotechnology - Labmate Online - March 18th, 2024
- The twelve hottest biotech companies in the Boston area - Labiotech.eu - March 18th, 2024
- Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off - The Globe and Mail - March 10th, 2024
- Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation - Simply Wall St - March 10th, 2024
- The Top 25 Biotechnology Companies of 2024 - The Healthcare Technology Report. - March 10th, 2024
- Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature ... - Nature.com - March 10th, 2024
- MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain ... - Business Wire - March 10th, 2024
- Global Pharmaceuticals and Biotechnology Distribution Deals Analysis Report and Directory 2024: Breakdown of ... - PR Newswire - March 10th, 2024
- Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of ... - PR Newswire - March 10th, 2024
- INTERNATIONAL BIOTECHNOLOGY TRUST has a healthy attitude towards paying investors - This is Money - March 10th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Biotechnology should be high on the agenda at the Munich Security Conference - The Hill - February 18th, 2024
- Boston is best in the world at biotech. Beijing wants to do it better - WBUR News - February 18th, 2024
- Multiomics Are The Next Step In Biotechnology - Securities.io - February 18th, 2024
- SPARKing academic technologies across the valley of death - Nature.com - February 18th, 2024
- Is Nurix Therapeutics Inc (NRIX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Addressing the Threat to U.S. Biotechnology: Concerns Over Genetic Data Security - Medriva - February 18th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- Is Tempest Therapeutics Inc (TPST) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Immunome Inc (IMNM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Larimar Therapeutics Inc (LRMR) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- US lawmakers, visiting Cambridge, warn of a rising Chinese threat to US biotech - The Boston Globe - February 18th, 2024
- Should Biotechnology Stock Viking Therapeutics Inc (VKTX) Be in Your Portfolio Monday? - InvestorsObserver - February 18th, 2024
- How the push to limit Chinese biotech could threaten U.S. edge - Axios - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- BioAro Inc to Host Inaugural Longevity Innovation Forum in Dubai, UAE - Yahoo Finance - January 25th, 2024
- Is Akebia Therapeutics Inc (AKBA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - January 25th, 2024
- Agricultural Biotechnology Market Projected to Reach USD 64.7 billion, with Advancing CAGR of 9.5% by 2031 ... - Yahoo Finance - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- ZWI Therapeutics Announces Closing of $10M Series A Financing - FinSMEs - January 25th, 2024
- Breaking Barriers: Tiamat Sciences Shatters Norms with All-Female Executive Team - Yahoo Finance - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Is Cabaletta Bio Inc (CABA) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Why Investors and Media are Calling Biotech Showcase The Place to Be to Start the Year - Business Wire - January 25th, 2024
- Is IGC Pharma Inc (IGC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Is Summit Therapeutics Inc (SMMT) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Biotech Stocks: The Top 5 To Watch As Shares Trend Down - Investor's Business Daily - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- HRMY: Are These 3 Biotech Stocks Worth Buying? - StockNews.com - January 25th, 2024
- Global Preparative Chromatography Market is projected to reach US$ 2,139.4 Million by 2034 Amid Growing ... - Yahoo Finance - January 25th, 2024
- Is Immunome Inc (IMNM) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023